Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3
Section snippets
Comparative study
Thirty Fabry patients from the Academic Medical Center (AMC) and 1 patient from the Universitatsklinikum Wurzburg (UKW) who were treated with agalsidase alfa (n = 18) or beta (n = 13) at 0.2 mg/kg for a minimum of 12 months were included in the study. Twenty nine of the AMC patients had been part of the head-to-head study [11]. In addition 5 patients from the AMC and 16 patients from the UKW who had been receiving agalsidase beta at 1.0 mg/kg for at least 12 months were included.
Switch study
Biochemical
Baseline characteristics
The baseline characteristics of the 52 patients included in the study are shown in Table 1. There were no significant differences between the 3 treatment groups with respect to age, sex and levels of biochemical parameters at baseline. Patients in the switch study were 7 males (3, agalsidase alfa 0.2 mg/kg and 4, agalsidase beta 0.2 mg/kg) who switched to agalsidase beta 1.0 mg/kg because of progression of disease (i.e. treatment failure [11]). All patients had significant symptomatology before
Discussion
This study shows that neutralizing antibodies are produced in the majority of male Fabry disease patients undergoing ERT and that they interfere with the excretion of GL-3. Persistent high titers of antibodies occurred in males who had switched from 0.2 mg/kg to 1.0 mg/kg treatment In line with Linthorst et al [14] we found 64% (18/28) of male patients developing IgG antibodies with neutralizing capacities within the first 6 months of treatment. The occurrence of antibodies was not associated
Disclosure
Anouk C. Vedder, Johannes M.F.G. Aerts and Carla E.M. Hollak receive reimbursement of expenses and small honoraria for lectures on the management of lysosomal storage diseases, including Fabry disease, from Genzyme Corporation and Shire. All honoraria are donated to the Gaucher Stichting, a national foundation that supports research in the field of lysosomal storage disorders. Frank Breunig received lecture fees from Genzyme Corporation and Shire. Christoph Wanner received grant support for
Acknowledgments
The authors gratefully thank Sijmen Kuiper Aldi Poppema, Karen Ghauharali and Els Ormel for handling of blood and urine samples.
References (35)
- et al.
Clinical benefit of enzyme replacement therapy in Fabry disease
Kidney Int.
(2006) - et al.
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
Am. J. Hum. Genet.
(2004) - et al.
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta
Kidney Int.
(2004) - et al.
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy
Mol. Genet. Metab.
(2007) - et al.
Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy
Mol. Genet. Metab.
(2006) Immunogenicity of therapeutic proteins: clinical implications and future prospects
Clin. Ther.
(2002)- et al.
Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry’s disease
Clin. Chim. Acta
(1981) - et al.
Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase
J. Biol. Chem.
(2003) - et al.
Monitoring of Gaucher patients with a novel chitotriosidase assay
Clin. Chim. Acta
(2007) - et al.
Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study
Am. J. Cardiol.
(1987)